30.5 C
Vientiane
Friday, May 30, 2025
spot_img
Home Blog Page 618

Veeva CRM Pulse Improves Segmentation and Targeting with Brick-Level HCP Access Data for 21 Countries

Delivered quarterly, CRM Pulse is generated from more than 500 million Veeva CRM interactions for the industry’s most complete, timely, and accurate HCP access data

SINGAPORE, March 5, 2025 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced Veeva CRM Pulse, a data subscription that provides quarterly healthcare professional (HCP) access and multichannel engagement metrics for the life sciences industry. With HCP access data as an input for segmentation, targeting, and engagement planning, Pulse provides immediate value for commercial operations and data analytics teams.

Pulse is unique in giving customers HCP data that has:

  • True Industry Census: Based on global usage of Veeva’s leading CRM Suite, Pulse is the most complete, timely, and accurate data set for HCP access.
  • Unmatched Coverage: Access and engagement metrics by channel are available for more than three million HCPs across 102 specialties and 21 countries.
  • Aggregated for Data Privacy: HCP metrics are segmented and aggregated by country, specialty, and brick for data privacy.

“Pulse is a breakthrough data product that will greatly improve segmentation and targeting around the globe,” said Peter Stark, executive vice president of Veeva Data Cloud. “We look forward to working with our early customers to bring the value of CRM Pulse data to their commercial operations.”

Pulse is available for license to Veeva’s CRM customers today with 2024 quarterly data covering the United States, Canada, Germany, United Kingdom, France, Italy, Spain, Portugal, Austria, Switzerland, Netherlands, Belgium, Ireland, Hungary, Brazil, Mexico, Australia, New Zealand, South Korea, Taiwan, and Singapore. Quarterly data releases for 2025 will begin this April. Additional countries in Asia and Europe are planned for availability next year.

Veeva CRM Pulse is part of Veeva Data Cloud, which includes Veeva OpenData, Veeva Link, and Veeva Compass. For more information, visit veeva.com/Pulse.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

 

CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland

  • CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities across Europe and the US.
  • In Switzerland, CordenPharma will invest >€500m to construct a greenfield site for small to large-scale peptide development and manufacturing located within the Basel region in Muttenz.
  • In its Colorado, US site, ongoing expansion will target additional large-scale peptide manufacturing capacity of existing lines as well as a greenfield construction for new production areas.

BASEL, Switzerland, March 5, 2025 /PRNewswire/ — Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion strategic investment in peptide development and manufacturing. The company’s ambitious expansion plans are set to propel its Peptide Platform business beyond the €1 billion sales milestone by 2028, reinforcing CordenPharma’s position as a market leader in integrated supply of small to large-scale services from APIs to Drug Products, for both Injectable and Oral Peptides.

[Photo by CordenPharma] An aerial sketch of CordenPharma’s future peptide manufacturing facility located at Getec Park in Muttenz, Switzerland.
[Photo by CordenPharma] An aerial sketch of CordenPharma’s future peptide manufacturing facility located at Getec Park in Muttenz, Switzerland.

As part of this strategy, CordenPharma has finalized plans to establish a state-of-the-art peptide manufacturing facility in Switzerland located at Getec Park in Muttenz, just 8 km outside Basel – a major biotech and pharma hub within Europe.

The decision to locate the plant near Basel is supported by several key advantages, including:

  • Efficient infrastructure, with existing systems for handling materials and processes that are crucial for state-of-the-art peptide manufacturing.
  • Optimal logistics, with streamlined access to transportation networks.
  • Established large-scale utilities already in place to support chemical manufacturing needs.
  • Talent pool access due to close proximity to Basel, a renowned pharma and biotech hub at the crossroads of Germany, France, and Switzerland, ensuring access to highly skilled professionals.
  • The surrounding industrial park ensures sustainable operational efficiency in a well-established manufacturing ecosystem with closed-loop energy and material cycles, as well as innovative waste-to-value streams, with a clear strategic path to net-zero.

This >€500 million investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale Solid Phase Peptide Synthesis (SPPS) reactors for GLP-1 and non-GLP-1 peptide projects – with a total SPPS reactor capacity of more than 5,000 L. The new state-of-the-art facility will feature advanced automation, cutting-edge digitalization, and innovative peptide production technologies, ensuring compliance with the most stringent regulations, including BLA requirements. With the main construction and qualification phase taking place between 2025 and 2027 and start of commercial activities to begin in the first half of 2028, the company is proud to generate over 300 new jobs, contributing to economic growth and innovation of the region.

In their Boulder, Colorado US facility, both expansions to existing lines and the construction of a new greenfield production area have already begun in parallel to the Switzerland initiative. The expansion will more than double the existing SPPS reactor capacity at CordenPharma Colorado by adding an additional 25,000 L of SPPS capacity – making it a total reactor capacity of >42,000 L by 2028.

Once fully operational, the Switzerland site – together with the ongoing expansions and additional greenfield capacity at CordenPharma Colorado – will significantly enhance the company’s production capabilities, solidifying CordenPharma’s position as one of the largest peptide manufacturing partners leading the CDMO peptide space.

Dr. Michael Quirmbach, President & CEO of CordenPharma Group comments: “We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland, within one of the leading pharma and biotech hubs in Europe. The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for our customers and ultimately, patients.”

Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: “CordenPharma’s bold expansion reflects its leadership in addressing the growing demand for peptide manufacturing. As a long-term investor, we are fully committed to supporting this growth, combining industrial excellence with strategic investment to strengthen CordenPharma’s position as a leading global CDMO. Ultimately, this expansion contributes to expanding access to those life-saving peptide-based medicines for patients.”

CordenPharma was acquired by Astorg, a leading Pan-European private equity firm, in 2022 to accelerate its development plans. With Astorg’s backing and these expansions, CordenPharma is well-positioned to execute its growth strategy and further strengthen its leadership in the CDMO peptide space.

About CordenPharma

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees.

Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.

About Astorg

Astorg is a leading pan-European private equity firm with over €23 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software and technology, business services and technology-based industrial companies. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan.

For more information about Astorg: www.astorg.com | Follow Astorg on LinkedIn.

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).
CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

Photo – https://laotiantimes.com/wp-content/uploads/2025/03/cordenpharma_aerial_sketch_of_new_peptide_greenfield_construction_near_basel_switzerland_2025_web.jpg 

Logo – https://laotiantimes.com/wp-content/uploads/2025/03/cordenpharma_logo_new.jpg

New Vehicle Tracking Sheet Requirement at Lao-Thai Friendship Bridge Starting 3 March

New Vehicle Tracking Sheet Requirement at Lao-Thai Friendship Bridge Starting 3 March
New Vehicle Tracking Sheet Requirement at Lao-Thai Friendship Bridge Starting 3 March

Starting 3 March, all vehicles crossing the Lao-Thai Friendship Bridge 1, connecting Vientiane, Laos, with Nong Khai, Thailand, will be required to purchase and submit a tracking sheet to immigration authorities. This new procedure, aimed at enhancing border security, mandates that vehicle owners and passengers complete and submit tracking sheets during border crossings.

New Vehicle Tracking Sheet
New Vehicle Tracking Sheet

Departure Procedures

As travelers prepare to leave Laos via the Lao-Thai Bridge, they must first purchase a tracking sheet from an officer for a fee of LAK 10,000 in cash. This document is essential for tracking the movement of vehicles and passengers. Once obtained, they need to carefully fill in all required details, including information about the vehicle, its owner, any passengers, and the intended destination.

With the completed tracking sheet in hand, travelers must then proceed to the departure officer, where they present their passport or border pass for verification. After identity confirmation, the next step involves paying the required tax LAK 8,000 per identification document at a customs machine or directly to an attending staff member. Once payment is made, a receipt is issued, which must be shown to the customs officer. 

Finally, IDs and the tax bill are submitted to immigration, marking the completion of the exit process.

Arrival Procedures

Upon returning to Laos, travelers must first present their passport or border pass to the arrival officer for verification. This step ensures that their entry is recorded properly. 

As part of the final procedures, those who previously obtained a tracking sheet must return it to the customs officer to complete the documentation process. 

Enhancing Border Security

This initiative, as outlined in the official announcements, aims to enhance security and regulatory measures at border crossings, ensuring lawful movement between Laos and Thailand. 

According to the official government notice, a key objective of the new tracking paper system is to prevent human trafficking by enforcing stricter procedures and requiring detailed documentation to identify and stop trafficking attempts. The system also aims to curb the import and export of illegal and hazardous items, such as weapons, explosives, poisons, narcotics, and other restricted substances. Additionally, it is designed to help detect and prevent activities related to money laundering, terrorism, transnational crime, and the illegal trade of protected wildlife. 

However, specific details on how the tracking paper will practically contribute to the prevention of these illegal activities have not been disclosed.

 

Workato and Tata Consultancy Services Form Strategic Alliance to Deliver Next-Gen Innovation and Help Companies Modernise Legacy Systems

The alliance will advise companies on how to streamline operational processes, accelerate digital transformation and drive faster innovation.


SINGAPORE – Media OutReach Newswire – 5 March 2025 – Workato®, the leading enterprise orchestration platform, announced a new strategic alliance with Tata Consultancy Services (TCS), a global leader in IT services, consulting and business solutions. The TCS and Workato alliance is a commitment to help businesses streamline operations, drive productivity and embrace innovation. With this collaboration, Workato and TCS will strengthen their joint enterprise orchestration capabilities to enable digital transformation and technology modernisation for their customers.

Named a Leader in the 2024 Gartner® Magic Quadrant™ for iPaaS, Workato enables enterprises to transform their business operations by orchestrating business processes end-to-end and operationalizing AI across the entire organization. The company’s low-code/no-code platform is designed to make it easy for Information Technology and business teams to integrate their applications, data, and experiences while maintaining security and governance. Workato’s AI-powered agentic capabilities allow customers to rapidly build and manage powerful AI agents that take action and orchestrate workflows.

“Today, customers need to rationalize and simplify their technology spread. They are investing in platforms that can help them automate, improve productivity, and deliver efficiencies across the enterprise landscape. Workato, with its integration, automation and AI capabilities, helps simplify, automate, and deliver significant cost savings to customers. TCS, with its deep domain and technology expertise, has been working with Workato to help customers define their integration roadmap, simplify technology landscape, and deliver more with less through automation and AI,” said Punit Agarwal, Singapore Country Head, Tata Consultancy Services.

Over 200 TCS practitioners have been trained on the Workato platform and have completed Workato’s implementation certifications. By leveraging the power of Workato’s platform, TCS will help its extensive network of clients deliver custom solutions to address complex business problems and accelerate digitalisation. This includes integrating data across enterprise systems, modernising legacy applications, automating repetitive and manual tasks, and embracing AI-powered enterprise orchestration.

“The enterprise IT landscape is changing rapidly as a result of evolving business demands, cloud adoption, and digital transformation initiatives. Enterprises are facing the convergence of integration and automation solutions which seamlessly connect enterprise applications, implement business process orchestration, and enable human tasks and workflows to unlock the true potential of siloed enterprise data for intelligent, data-driven business growth,” said Kiran Deshpande, Global Enterprise Integration Practice Head, Tata Consultancy Services.

“Workato’s AI-powered, hyper-automation platform along with TCS’ domain, contextual, and technology knowledge, enables customers in their digital transformation initiatives for accelerated business growth,” he added.

“We are thrilled to embark on this strategic alliance with TCS, a global leader in business solutions consulting and digital transformation. By joining forces with TCS and leveraging their extensive network and industry expertise, we’re well-positioned to help more enterprises in Asia Pacific pursue AI-powered efficiency, productivity and innovation across their business,” said June Lee, General Manager, Workato Asia Pacific.

“Together, our partnership will provide an unmatched combination of strategic consultancy based on deep industry knowledge and AI-driven workflow orchestration capabilities, to deliver unparalleled value to our joint customers.”
Hashtag: #Workato




The issuer is solely responsible for the content of this announcement.

Workato

Workato transforms technology complexity into business opportunity. As the leader in enterprise orchestration, Workato helps businesses globally streamline operations by connecting data, processes, applications, and experiences. Its AI-powered platform enables teams to navigate complex workflows in real time, driving efficiency and agility. Trusted by over 12,000 global customers, Workato empowers organizations of every size to unlock new value and lead in today’s fast-changing world. Learn how Workato helps businesses of all sizes achieve more at www.workato.com.

Tata Consultancy Services

Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for over 56 years. Its consulting-led, cognitive powered, portfolio of business, technology and engineering services and solutions is delivered through its unique Location Independent Agile™ delivery model, recognized as a benchmark of excellence in software development.

A part of the Tata group, India’s largest multinational business group, TCS has over 607,000 of the world’s best-trained consultants in 55 countries. The company generated consolidated revenues of US $29 billion in the fiscal year ended March 31, 2024, and is listed on the BSE and the NSE in India. TCS’ proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit .

PAObank Receives Insurance Agency Licence, Announces the Strategic Partnership with China Ping An Insurance (Hong Kong) and FWD Hong Kong Respectively

Offering Both General and Life Insurance to Meet Customers’ Various Protection Needs


HONG KONG SAR – Media OutReach Newswire – 5 March 2025 – PAO Bank Limited (“PAObank”) announced that it has been granted an Insurance Agency Licence from the Insurance Authority (“IA”) and has signed strategic partnership agreements with China Ping An Insurance (Hong Kong) Company Limited (“PAHK”) and FWD Hong Kong (“FWD”) respectively. PAObank is launching both general and life insurance services, offering retail banking customers a seamless bancassurance experience.

PAObank has entered into a bancassurance partnership with PAHK, leveraging on their extensive general insurance expertise as a solid support for this collaboration, to provide a wide array of diverse products, including motor insurance, travel insurance, and home insurance solutions to meet customers’ various protection needs.

Meanwhile, PAObank has further deepened its partnership with insurer, FWD, following the successful launch of Hong Kong’s first bank-insurance “Commercial Data Interchange” (CDI) collaboration, which promotes cross-sector data interchange and leads breakthroughs in the data integration and applications for Hong Kong’s financial sectors. PAObank and FWD are now expanding their collaboration to retail banking, offering life insurance products to customers.

By seamlessly integrating financial technology and Application Programming Interface (API) technology, PAObank connects with insurance companies’ platforms to offer comprehensive online one-stop insurance services. Customers can now easily purchase insurance at their fingertips, enjoying a more convenient, seamless, and secure insurance experience. With just a few simple steps, they can ensure reliable protection for themselves and their families.

Mr. Ambrose Wong, Chief Executive of PAObank, said, “Obtaining the Insurance Agency Licence is a pivotal milestone for the development of our retail banking services. We are delighted to have reached a strategic partnership agreement with PAHK and FWD respectively to further expand our financial services offerings for our individual customers. In addition to time deposits and insurance services, we are accelerating efforts to launch more insurance products. With a focus on serving SMEs and individual customers, we aim to provide a diverse array of financial services, creating greater value for our clients.”

Mr. Kelvin Cheung, Managing Director of PAHK stated, “The online insurance business of PAHK provides customers with 24/7 online instant quotes and insurance application services, significantly improving customer experience and striving to achieve the concept of ‘humanised financial services’. We are very pleased to collaborate with PAObank to offer excellent protection plans and services to our customers.”

Mr. Ken Lau, Managing Director of Greater China and Hong Kong Chief Executive Officer, FWD said, “We are delighted to further strengthen our strategic partnership with PAObank. FWD is actively expanding our multi-channel distribution strategy to serve more customers through our bancassurance partnership network. Through this collaboration, FWD will provide more customers with life insurance products, working hand in hand with PAObank to bring greater benefits to both parties.”

PAObank will continue to innovate and leverage financial technology to provide SMEs and individual customers with comprehensive, convenient, and personalised financial solutions. At the same time, PAObank will continue to establish a sustainable financial ecosystem and facilitate the development of digital banking.

Please refer to the PAObank website at www.paob.com.hk for details. For any enquiries, please contact us through Live Chat in the PAObank APP or call the customer services hotline at 3762 9900.
Hashtag: #PAObank #PAHK #FWD #Bancassurance

The issuer is solely responsible for the content of this announcement.

PAO Bank Limited

PAO Bank Limited (“PAObank”), a wholly-owned subsidiary of Lufax Holding Ltd (“Lufax”) (SEHK: 6623; NYSE: LU) and a member of Ping An Insurance (Group) Company of China, Ltd. (“Ping An”) (SEHK: 2318; SSE: 601318), is committed to fostering financial inclusion and establishing a digital banking ecosystem by leveraging its extensive experience in SME banking services and its leading financial technology advantages. PAObank was granted a banking licence by the Hong Kong Monetary Authority in May 2019 to offer banking services via digital channels. PAObank is expanding diverse business segments including retail banking and SME banking.

China Ping An Insurance (Hong Kong) Company Limited

China Ping An Insurance (Hong Kong) Company Limited boasts a well-established operational framework and a professional management team, continuously advancing diversified insurance businesses to keep pace with market trends and meet the needs of large enterprises, small and medium-sized enterprises, and individual customers. The company actively promotes the concept of “humanized financial services”. Since 2010, the company has successfully expanded its online insurance business, bringing new opportunities to the development of general insurance. Customers can now enjoy 24/7 online instant quotation and insurance application services, allowing them to choose the right protection for themselves and their families anytime and anywhere. The online application process requires no document submission, with the entire process taking as little as 5 minutes, fully automated with instant approval and policy issuance. All insurance products feature transparent and clear key terms, and customers can conveniently complete applications and renewals online. The company is committed to providing exceptional service to meet the diverse needs of its customers.

FWD Hong Kong

FWD Hong Kong is part of the FWD Group, a pan-Asian life and health insurance business with more than 12 million customers across 10 markets, including some of the fastest-growing insurance markets in the world. FWD is a top five insurer in Hong Kong*.

FWD Hong Kong has been assigned strong financial ratings by international agencies. It offers life and medical insurance, employee benefits, and financial planning.

The company was established in 2013 and is focused on making the insurance journey simpler, faster and smoother, with innovative propositions and easy-to-understand products, supported by digital technology. Through this customer-led approach, FWD is committed to changing the way people feel about insurance.

For more information about FWD Hong Kong please visit www.fwd.com.hk.

*According to Provisional Statistics on Hong Kong Long Term Insurance Business – January to December in 2023, Insurance Authority of Hong Kong, 《Pi Financial Services Intelligence report》- December 2022 and December 2023, as well as FWD’s own assessment based on its understanding on the statistics and market information, FWD ranks top five in new business case count, net growth of life insurance intermediaries’ headcount, tied agency channel new business FYP, brokerage channel new business FYP, bancassurance channel new business FYP, as well as online and direct platform new business case count.

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene’s Commercial Presence in APAC

– XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.

– From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene’s commercial presence in APAC. To date, XPOVIO® has been approved for multiple indications in ten markets across the APAC region.

– XPOVIO® has been approved for health insurance coverage in the mainland of China, Taiwan market, Australia, Singapore and South Korea.

SHANGHAI and HONG KONG, March 5, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for three indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy;(2) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs), and an anti‐CD38 monoclonal antibody; and (3) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy who are not eligible for haematopoietic cell transplant.

With a novel mechanism of action, XPOVIO® is the world’s first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea).

The ASEAN region, with its steady economic growth and a population exceeding 600 million, has become a market of significant potential for global biomedical development. The accelerating aging population in ASEAN has increased the overall disease burden on patients and local communities, leading to a growing demand for novel therapeutics. Currently, Antengene is actively expanding its presence into APAC markets in efforts to introduce more innovative medicines to the ASEAN region in the future, improving the level of healthcare in these regions and benefiting more patients in need.

While bringing XPOVIO® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO®. Leveraging the drug’s novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer.

About XPOVIO® (selinexor)

XPOVIO® is the world’s first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses.

By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]).

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”.

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com 
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000

New TXOne Networks OT/ICS Cybersecurity Report Details Growing Range of Risks Facing Companies as Digital Transformation Unfolds Globally

Supply-chain vulnerabilities, aging infrastructure, patching difficulties and gaps in incident response demand urgent action to safeguard industrial operations, TXOne Networks report shows

TAIPEI, March 5, 2025 /PRNewswire/ — TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, published its new annual report on operational technology (OT) cybersecurity, detailing risks such as supply-chain vulnerabilities, aging infrastructure, patching difficulties and gaps in incident response. The new report, which is publicly available for free download, reveals heightened concerns over digital vulnerabilities potentially introduced in deployment of industrial control systems (ICS) such as smart sensors, edge-computing devices, asset-tracking solutions and remote-monitoring tools. 

TXOne 2024 OT/ICS Cybersecurity Report
TXOne 2024 OT/ICS Cybersecurity Report

“How can organizations effectively secure these interconnected systems against cyber threats? This is the pressing challenge confronting Chief Information Security Officers (CISOs) worldwide,” reads TXOne Networks’ 2024 Annual OT/ICS Cybersecurity Report. “Traditionally, cybersecurity strategies have focused on safeguarding IT (information technology) systems and their digital assets. However, as industries undergo continuous digitalization, critical infrastructure is increasingly integrated into unified digital ecosystems, broadening the attack surface. The intrinsic differences between OT and IT systems often render IT-centric security measures inadequate when applied to OT environments. With OT systems now deeply interconnected, the shortcomings of conventional IT protections have become glaringly evident, particularly in light of the safety, availability, and reliability characteristics of these systems.”

The findings in the report are grounded in a large-scale survey conducted jointly by TXOne Networks and Frost & Sullivan, encompassing input from 150 C-suite executives from Asia, Europe, the Middle East and North America. The research covers multiple industrial sectors—automotive, food, oil and gas, pharmaceuticals and semiconductors, for example—each vital to the global economy and uniquely exposed to OT cybersecurity challenges.

The report showed that 94% of surveyed organizations reported being at risk of OT cyber incidents in the past year, while 98% experienced IT incidents affecting their OT environments. While ransomware incidents decreased from 47% of respondents in 2023 to 28% in 2024, nation-state attackers on critical infrastructure were revealed to be a growing new concern. Advanced Persistent Threats (APTs), vulnerabilities in supply-chain software and advanced malware such as Fuxnet and FrostyGoop are among the diverse threats documented in 2024 Annual OT/ICS Cybersecurity Report.

The TXOne Networks report goes on to illuminate key insights across a range of topics:

  • Changing threat landscape of OT environments
  • Prioritizing vulnerabilities and overcoming patching challenges
  • Regulation and standardization trends
  • Overcoming pitfalls and securing the future

“As large enterprises strengthen their security posture, the focus of OT cybersecurity is expanding beyond visibility to include protection, advanced threat detection, and robust security governance,” said Dr. Terence Liu, Chief Executive Officer (CEO) of TXOne Networks. “Asset discovery and vulnerability management are merely starting points. The persistent rise in OT cyberattacks, as highlighted in this year’s report, underscores the urgent need for organizations—especially those without dedicated OT security practices—to take action. Security vendors must lead the way by bridging gaps through knowledge sharing and innovation. At TXOne Networks, we are committed to raising global OT security standards and shaping a more resilient future for industrial cybersecurity.”

Download TXOne Networks’ 2024 Annual OT/ICS Cybersecurity Report. Follow TXOne Networks on Blog, Twitter, and LinkedIn.

About TXOne Networks

TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com 

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene’s Commercial Presence in APAC

– XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.

From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene’s commercial presence in APAC. To date, XPOVIO® has been approved for multiple indications in ten markets across the APAC region.

– XPOVIO® has been approved for health insurance coverage in the mainland of China, Taiwan market, Australia, Singapore and South Korea.

SHANGHAI and HONG KONG, March 5, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for three indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy;(2) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs), and an anti‐CD38 monoclonal antibody; and (3) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy who are not eligible for haematopoietic cell transplant.

With a novel mechanism of action, XPOVIO® is the world’s first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea).

The ASEAN region, with its steady economic growth and a population exceeding 600 million, has become a market of significant potential for global biomedical development. The accelerating aging population in ASEAN has increased the overall disease burden on patients and local communities, leading to a growing demand for novel therapeutics. Currently, Antengene is actively expanding its presence into APAC markets in efforts to introduce more innovative medicines to the ASEAN region in the future, improving the level of healthcare in these regions and benefiting more patients in need.

While bringing XPOVIO® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO®. Leveraging the drug’s novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer.

About XPOVIO® (selinexor)

XPOVIO® is the world’s first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses.

By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]).

 About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”.

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com 
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000